Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - Jounce Therapeutics, Inc. | jnce03312017exhibit312.htm |
| EX-31.1 - EXHIBIT 31.1 - Jounce Therapeutics, Inc. | jnce03312017exhibit311.htm |
| 10-Q - 10-Q - Jounce Therapeutics, Inc. | jnce0331201710-q.htm |
Exhibit 32.1
CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with this Quarterly Report on Form 10-Q of Jounce Therapeutics, Inc. (the “Company”) for the period ended March 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. (section) 1350, as adopted pursuant to (section) 906 of the Sarbanes-Oxley Act of 2002, that to the best of her or his knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 9, 2017 | By: | /s/ Richard Murray |
Richard Murray, Ph.D. | ||
President, Chief Executive Officer and Director | ||
(Principal Executive Officer) | ||
Date: May 9, 2017 | By: | /s/ Kim C. Drapkin |
Kim C. Drapkin | ||
Treasurer and Chief Financial Officer | ||
(Principal Financial and Accounting Officer) | ||